Superinfection exclusion limiting coinfection between distinct virus populations in vitro. by Anna Sims (14592855)

Improvement in neurocognitive testing in young adult rats after HIE by RLS-0071 alone and in combination with hypothermia. by Parvathi Kumar (11105382)

Performance of network with hyperpolarizing synapes is robust to different instantiations of network connectivity. by Guillem Via (14204815)

Muheza District map showing study area (schools) and respective households with pupils’ location. by Geofrey Makenga (12646903)

B12A-05: A review and synthesis of nitrogen inputs, outputs and dynamics to support the implementation of nitrogen cap reduction in the Lake Rotorua catchment. by Troy Baisden (11213706)

“…Second, improving temporal and spatial detail for N loads to the lake in major streams was the most important factor to improve model performance. A separate trend evaluation found unexpected flat and decreasing inflow nitrate concentrations in catchments with long tritium-derived mean residence times. …”

Lansoprazole changes the production levels of several Aβ species. by Nahuai Badiola (199596)

“…A decrease on Aβ38 and increase on Aβ42 was detected in conditioned media of treated cells with lansoprazole at 50 µM for 24 h. …”

Leptospiral burdens in hamsters infected with 10⁷ <i>Leptospira</i>. by Jiaqi Wang (369548)

Uncovering Urinary Proteome Differences in Very Preterm Infants with and without Preterm Brain Injury by Magdalena Zasada (4524901)

Image_1_SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.tif by Monica Franzese (8983097)

“…The cohorts were monitored from the 12th day after the first vaccine dose up to 1 month after the third vaccine dose for a total of eight time points and about 1 year of surveillance (T1 = 12 days after the first dose; T2 = 10 days after the second dose; T3 = 1 month after the second dose; T4 = 3 months after the second dose; T5 = 4 months after the second dose; T6 = 5 months after the second dose; T7 = 7 months after the second dose; T8 = 1 month after the third dose for Group 1; T8* = 9 months after the second dose for Group 2; T9 = 1 month after the third dose for Group 2). …”

Table_3_SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.xlsx by Monica Franzese (8983097)

“…The cohorts were monitored from the 12th day after the first vaccine dose up to 1 month after the third vaccine dose for a total of eight time points and about 1 year of surveillance (T1 = 12 days after the first dose; T2 = 10 days after the second dose; T3 = 1 month after the second dose; T4 = 3 months after the second dose; T5 = 4 months after the second dose; T6 = 5 months after the second dose; T7 = 7 months after the second dose; T8 = 1 month after the third dose for Group 1; T8* = 9 months after the second dose for Group 2; T9 = 1 month after the third dose for Group 2). …”

Table_6_SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.xlsx by Monica Franzese (8983097)

“…The cohorts were monitored from the 12th day after the first vaccine dose up to 1 month after the third vaccine dose for a total of eight time points and about 1 year of surveillance (T1 = 12 days after the first dose; T2 = 10 days after the second dose; T3 = 1 month after the second dose; T4 = 3 months after the second dose; T5 = 4 months after the second dose; T6 = 5 months after the second dose; T7 = 7 months after the second dose; T8 = 1 month after the third dose for Group 1; T8* = 9 months after the second dose for Group 2; T9 = 1 month after the third dose for Group 2). …”

Table_4_SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.xlsx by Monica Franzese (8983097)

“…The cohorts were monitored from the 12th day after the first vaccine dose up to 1 month after the third vaccine dose for a total of eight time points and about 1 year of surveillance (T1 = 12 days after the first dose; T2 = 10 days after the second dose; T3 = 1 month after the second dose; T4 = 3 months after the second dose; T5 = 4 months after the second dose; T6 = 5 months after the second dose; T7 = 7 months after the second dose; T8 = 1 month after the third dose for Group 1; T8* = 9 months after the second dose for Group 2; T9 = 1 month after the third dose for Group 2). …”

Table_2_SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.xlsx by Monica Franzese (8983097)

“…The cohorts were monitored from the 12th day after the first vaccine dose up to 1 month after the third vaccine dose for a total of eight time points and about 1 year of surveillance (T1 = 12 days after the first dose; T2 = 10 days after the second dose; T3 = 1 month after the second dose; T4 = 3 months after the second dose; T5 = 4 months after the second dose; T6 = 5 months after the second dose; T7 = 7 months after the second dose; T8 = 1 month after the third dose for Group 1; T8* = 9 months after the second dose for Group 2; T9 = 1 month after the third dose for Group 2). …”

Table_1_SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.xlsx by Monica Franzese (8983097)

“…The cohorts were monitored from the 12th day after the first vaccine dose up to 1 month after the third vaccine dose for a total of eight time points and about 1 year of surveillance (T1 = 12 days after the first dose; T2 = 10 days after the second dose; T3 = 1 month after the second dose; T4 = 3 months after the second dose; T5 = 4 months after the second dose; T6 = 5 months after the second dose; T7 = 7 months after the second dose; T8 = 1 month after the third dose for Group 1; T8* = 9 months after the second dose for Group 2; T9 = 1 month after the third dose for Group 2). …”

Reference mutations versus background noise across replicates. by Lizhi Yu (12476136)

Analytical sensitivity and reproducibility. by Lizhi Yu (12476136)

Data_Sheet_1_Characterization of a Novel Functional Trimeric Catechol 1,2-Dioxygenase From a Pseudomonas stutzeri Isolated From the Gulf of Mexico.docx by Julieta Rodríguez-Salazar (8931386)

“…The purified PsC12DO enzyme was found as an active trimer, with a molecular mass of 107 kDa. Increasing NaCl concentration in the enzyme reaction gradually reduced activity; in high salt concentrations (0.7 M NaCl) quaternary structural analysis determined that the enzyme changes to a dimeric arrangement and causes a 51% decrease in specific activity on catechol substrate. …”

AAV8-Equine-IL10 improves EAU histology scores. by Elizabeth Crabtree (5685311)

“…The histological infiltrative scores (b) and structural scores (c) were significantly decreased in both low and high dose AAV8-Equine-IL10 treated eyes (n = 5 eyes) as compared to the BSS- EAU eyes (n = 4 eyes) (p = 0.010, p = 0.015 respectively; Wilcoxon test). …”

Depth of coverage and heterogeneity of the mutation loci. x-axis, mutation loci in sample set one or two; y-axis, depth of coverage after UMI consolidation. by Lizhi Yu (12476136)

Deviation from standard dose-response curve by bnMAbs in a U87 target cell assay. by Laura E. McCoy (386535)

“…The data points are colored according to which site the bnMAb targets: high-mannose patch (magenta), CD4bs (red), V2 apex (blue), and MPER (green). …”